↓ Skip to main content

UroMark—a urinary biomarker assay for the detection of bladder cancer

Overview of attention for article published in Clinical Epigenetics, January 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#16 of 684)
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news
3 news outlets
twitter
20 tweeters
reddit
1 Redditor

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
65 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
UroMark—a urinary biomarker assay for the detection of bladder cancer
Published in
Clinical Epigenetics, January 2017
DOI 10.1186/s13148-016-0303-5
Pubmed ID
Authors

Andrew Feber, Pawan Dhami, Liqin Dong, Patricia de Winter, Wei Shen Tan, Mónica Martínez-Fernández, Dirk S. Paul, Antony Hynes-Allen, Sheida Rezaee, Pratik Gurung, Simon Rodney, Ahmed Mehmood, Felipe Villacampa, Federico de la Rosa, Charles Jameson, Kar Keung Cheng, Maurice P. Zeegers, Richard T. Bryan, Nicholas D. James, Jesus M. Paramio, Alex Freeman, Stephan Beck, John D. Kelly

Abstract

Bladder cancer (BC) is one of the most common cancers in the western world and ranks as the most expensive to manage, due to the need for cystoscopic examination. BC shows frequent changes in DNA methylation, and several studies have shown the potential utility of urinary biomarkers by detecting epigenetic alterations in voided urine. The aim of this study is to develop a targeted bisulfite next-generation sequencing assay to diagnose BC from urine with high sensitivity and specificity. We defined a 150 CpG loci biomarker panel from a cohort of 86 muscle-invasive bladder cancers and 30 normal urothelium. Based on this panel, we developed the UroMark assay, a next-generation bisulphite sequencing assay and analysis pipeline for the detection of bladder cancer from urinary sediment DNA. The 150 loci UroMark assay was validated in an independent cohort (n = 274, non-cancer (n = 167) and bladder cancer (n = 107)) voided urine samples with an AUC of 97%. The UroMark classifier sensitivity of 98%, specificity of 97% and NPV of 97% for the detection of primary BC was compared to non-BC urine. Epigenetic urinary biomarkers for detection of BC have the potential to revolutionise the management of this disease. In this proof of concept study, we show the development and utility of a novel high-throughput, next-generation sequencing-based biomarker for the detection of BC-specific epigenetic alterations in urine.

Twitter Demographics

The data shown below were collected from the profiles of 20 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 65 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 17 26%
Student > Bachelor 8 12%
Student > Ph. D. Student 6 9%
Student > Master 6 9%
Other 6 9%
Other 13 20%
Unknown 9 14%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 22 34%
Medicine and Dentistry 15 23%
Agricultural and Biological Sciences 9 14%
Computer Science 2 3%
Arts and Humanities 1 2%
Other 3 5%
Unknown 13 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 36. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 June 2018.
All research outputs
#487,167
of 13,784,591 outputs
Outputs from Clinical Epigenetics
#16
of 684 outputs
Outputs of similar age
#18,914
of 347,682 outputs
Outputs of similar age from Clinical Epigenetics
#1
of 11 outputs
Altmetric has tracked 13,784,591 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 684 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 347,682 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.